Foundation Fighting Blindness Launches Human Study To Treat Blinding Disease With Valproic Acid
The Foundation Fighting Blindness has launched a Phase II clinical trial of valproic acid, now underway, to evaluate the drug's effectiveness in slowing vision loss for people with autosomal dominant forms of retinitis pigmentosa (adRP), an inherited retinal degeneration that progressively leads to blindness. Autosomal dominant forms affect multiple generations within families.